Correction to Lancet Gastroenterol Hepatol 2017; 2: 103–11 (Characteristics, management, and outcomes of patients with hepatocellular carcinoma in Africa: a multicountry observational study from the Africa Liver Cancer Consortium (2017) 2(2) (103–111), (S2468125316301613), (10.1016/S2468-1253(16)30161-3));Characteristics, management, and outcomes of patients with hepatocellular carcinoma in Africa: a multicountry observational study from the Africa Liver Cancer Consortium

The Lancet Gastroenterology and Hepatology

Volumn 2, Issue 2, 2017, Pages 103-111

  Yang, Ju Dong ^a   Mohamed, Essa A ^a   Aziz, Ashraf O Abdel ^b   Shousha, Hend I ^b   Hashem, Mohamed B ^b   Nabeel, Mohamed M ^b   Abdelmaksoud, Ahmed H ^b   Elbaz, Tamer M ^b   Afihene, Mary Y ^c   Duduyemi, Babatunde M ^c   Ayawin, Joshua P ^c   Gyedu, Adam ^c   Lohouès Kouacou, Marie Jeanne ^d   Ndam, Antonin W Ndjitoyap ^d   Moustafa, Ehab F ^e   Hassany, Sahar M ^e   Moussa, Abdelmajeed M ^e   Ugiagbe, Rose A ^f   Omuemu, Casimir E ^f   Anthony, Richard ^g   Palmer, Dennis ^h   Nyanga, Albert F ^h   Malu, Abraham O ⁱ   Obekpa, Solomon ⁱ   Abdo, Abdelmounem E ^j   Siddig, Awatif I ^j   Mudawi, Hatim M Y ^k   Okonkwo, Uchenna ^l   Kooffreh Ada, Mbang ^l   Awuku, Yaw A ^m   Nartey, Yvonne A ^m   Abbew, Elizabeth T ^m   Awuku, Nana A ^m   Otegbayo, Jesse A ⁿ   Akande, Kolawole O ⁿ   Desalegn, Hailemichael M ^o   Omonisi, Abidemi E ^p   Ajayi, Akande O ^p   Okeke, Edith N ^q   Duguru, Mary J ^q   Davwar, Pantong M ^q   Okorie, Michael C ^q   Mustapha, Shettima ^r   Debes, Jose D ^s,t   Ocama, Ponsiano ^u   Lesi, Olufunmilayo A ^v   Odeghe, Emuobor ^v   Bello, Ruth ^x   Onyekwere, Charles ^w   Ekere, Francis ^w   Igetei, Rufina ^w   Mah'moud, Mitchell A ^y   Addissie, Benyam ^a   Ali, Hawa M ^a   Gores, Gregory J ^a   Topazian, Mark D ^a   Roberts, Lewis R ^a   more..

^a MAYO CLINIC   (United States)

^b CAIRO UNIVERSITY   (Egypt)

^c KWAME NKRUMAH UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Ghana)

^d CHU de Cocody   (Côte d’Ivoire)

^e ASSIUT UNIVERSITY   (Egypt)

^f UNIVERSITY OF BENIN   (Nigeria)

^g Effia Nkwanta Regional Hospital   (Ghana)

^h Oncology Unit   (Cameroon)

ⁱ BENUE STATE UNIVERSITY   (Nigeria)

^j Ibnsina   (Sudan)

^k UNIVERSITY OF KHARTOUM   (Sudan)

^l UNIVERSITY OF CALABAR   (Nigeria)

^m School of Medical Sciences   (Ghana)

ⁿ UNIVERSITY OF IBADAN   (Nigeria)

^o ST PAUL S HOSPITAL MILLENNIUM MEDICAL COLLEGE   (Ethiopia)

^p EKITI STATE UNIVERSITY   (Nigeria)

^q UNIVERSITY OF JOS   (Nigeria)

^r UNIVERSITY OF MAIDUGURI   (Nigeria)

^s UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^t Arusha Lutheran Medical Centre   (Tanzania)

^u MAKERERE UNIVERSITY COLLEGE OF HEALTH SCIENCES   (Uganda)

^v LAGOS UNIVERSITY TEACHING HOSPITAL   (Nigeria)

^w LAGOS STATE UNIVERSITY TEACHING HOSPITAL   (Nigeria)

^x Dalhatu Araf Specialist Hospital   (Nigeria)

^y DUKE UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALPHA FETOPROTEIN; BILIRUBIN; SORAFENIB;

ADULT; AFRICA; AGE DISTRIBUTION; AGED; ARTICLE; CANCER EPIDEMIOLOGY; CANCER SIZE; CHEMOEMBOLIZATION; CHILD PUGH SCORE; COHORT ANALYSIS; FEMALE; HEALTH CARE POLICY; HEPATIC ENCEPHALOPATHY; HEPATITIS B; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER RESECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MEDIAN SURVIVAL TIME; MIDDLE AGED; MIXED INFECTION; MULTICENTER STUDY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; RETROSPECTIVE STUDY; THROMBOCYTE COUNT; TREATMENT OUTCOME; CLINICAL TRIAL; COMPLICATION; EGYPT; INCIDENCE; LIVER TUMOR; MORTALITY; ONSET AGE; PREVALENCE; SURVIVAL RATE;

ADULT; AFRICA; AGE OF ONSET; CARCINOMA, HEPATOCELLULAR; EGYPT; FEMALE; HEPATITIS C; HUMANS; INCIDENCE; LIVER NEOPLASMS; MALE; MIDDLE AGED; PREVALENCE; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 85012993542     PISSN: 24681253     EISSN: None     Source Type: Journal    
DOI: 10.1016/S2468-1253(22)00208-4     Document Type: Erratum

References (29)

1. 1 International Agency for Research on Cancer. Globocan 2012. www.globocan.iarc.fr (accessed July 1, 2016).
2. 2 Yang, JD, Roberts, LR, Hepatocellular carcinoma: a global view. Nat Rev Gastroenterol Hepatol 7 (2010), 448–458.
3. 3 de Martel, C, Ferlay, J, Franceschi, S, et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol 13 (2012), 607–615.
4. 4 Stanaway, JD, Flaxman, AD, Naghavi, M, et al. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. Lancet 388 (2016), 1081–1088.
5. 5 Sartorius, K, Sartorius, B, Aldous, C, Govender, PS, Madiba, TE, Global and country underestimation of hepatocellular carcinoma (HCC) in 2012 and its implications. Cancer Epidemiol 39 (2015), 284–290.
6. 6 Yang, JD, Gyedu, A, Afihene, MY, et al. Hepatocellular carcinoma occurs at an earlier age in Africans, particularly in association with chronic hepatitis B. Am J Gastroenterol 110 (2015), 1629–1631.
7. 7 Kirk, GD, Lesi, OA, Mendy, M, et al. The Gambia Liver Cancer Study: infection with hepatitis B and C and the risk of hepatocellular carcinoma in West Africa. Hepatology 39 (2004), 211–219.
8. 8 Umoh, NJ, Lesi, OA, Mendy, M, et al. Aetiological differences in demographical, clinical and pathological characteristics of hepatocellular carcinoma in The Gambia. Liver Int 31 (2011), 215–221.
9. 9 Abdelaziz, AO, Elbaz, TM, Shousha, HI, et al. Survival and prognostic factors for hepatocellular carcinoma: an Egyptian multidisciplinary clinic experience. Asian Pac J Cancer Prev 15 (2014), 3915–3920.
10. 10 de Martel, C, Maucort-Boulch, D, Plummer, M, Franceschi, S, World-wide relative contribution of hepatitis B and C viruses in hepatocellular carcinoma. Hepatology 62 (2015), 1190–1200.
11. 11 Aziz, AO, Omran, D, Nabeel, MM, et al. Aggressive treatment of performance status 1 and 2 HCC patients significantly improves survival–an Egyptian retrospective cohort study of 524 cases. Asian Pac J Cancer Prev 17 (2016), 2539–2543.
12. 12 Ladep, NG, Lesi, OA, Mark, P, et al. Problem of hepatocellular carcinoma in West Africa. World J Hepatol 6 (2014), 783–792.
13. 13 Mekonnen, HD, Sharma, S, Shewaye, A, Feld, J, Lulu, E, Major risk factors, clinical and laboratory characteristics of patients with hepatocellular carcinoma; a retrospective study at Tikur Anbassa hospital, Addis Ababa university, Addis Ababa, Ethiopia. Ethiop Med J 53 (2015), 127–132.
14. 14 Gong, YY, Egal, S, Hounsa, A, et al. Determinants of aflatoxin exposure in young children from Benin and Togo, West Africa: the critical role of weaning. Int J Epidemiol 32 (2003), 556–562.
15. 15 Tognarelli, J, Ladep, NG, Crossey, MM, et al. Reasons why West Africa continues to be a hotbed for hepatocellular carcinoma. Niger Med J 56 (2015), 231–235.
16. 16 Olivier, J, Tsimpo, C, Gemignani, R, et al. Understanding the roles of faith-based health-care providers in Africa: review of the evidence with a focus on magnitude, reach, cost, and satisfaction. Lancet 386 (2015), 1765–1775.
17. 17 Turner, PC, Sylla, A, Gong, YY, et al. Reduction in exposure to carcinogenic aflatoxins by postharvest intervention measures in west Africa: a community-based intervention study. Lancet 365 (2005), 1950–1956.
18. 18 Hainaut, P, Boyle, P, Curbing the liver cancer epidemic in Africa. Lancet 371 (2008), 367–368.
19. 19 Stulac, S, Binagwaho, A, Tapela, NM, et al. Capacity building for oncology programmes in sub-Saharan Africa: the Rwanda experience. Lancet Oncol 16 (2015), e405–e413.
20. 20 Harford, JB, Barriers to overcome for effective cancer control in Africa. Lancet Oncol 16 (2015), e385–e393.
21. 21 Eltabbakh, M, Zaghla, H, Abdel-Razek, W, et al. Utility and cost-effectiveness of screening for hepatocellular carcinoma in a resource-limited setting. Med Oncol, 32, 2015, 432.
22. 22 Gelband, H, Sankaranarayanan, R, Gauvreau, CL, et al. Costs, affordability, and feasibility of an essential package of cancer control interventions in low-income and middle-income countries: key messages from Disease Control Priorities, 3rd edition. Lancet 387 (2016), 2133–2144.
23. 23 Busolo, DS, Woodgate, RL, Cancer prevention in Africa: a review of the literature. Glob Health Promot 22 (2015), 31–39.
24. 24 PROLIFICA. West African treatment cohort for Hepatitis B (WATCH). https://clinicaltrials.gov/ct2/show/NCT02129829, 2011 (accessed July 1, 2016).
25. 25 Howell, J, Ladep, NG, Lemoine, M, et al. Prevention of liver fibrosis and cancer in Africa: the PROLIFICA project–a collaborative study of hepatitis B-related liver disease in west Africa. S Afr Med J 105 (2015), 185–186.
26. 26 Shimakawa, Y, Lemoine, M, Mendy, M, et al. Population-based interventions to reduce the public health burden related with hepatitis B virus infection in The Gambia, west Africa. Trop Med Health 42:suppl 2 (2014), 59–64.
27. 27 Chang, MH, You, SL, Chen, CJ, et al. Long-term effects of hepatitis B immunization of infants in preventing liver cancer. Gastroenterology 151 (2016), 472–480.
28. 28 Wichajarn, K1, Kosalaraksa, P, Wiangnon, S, Incidence of hepatocellular carcinoma in children in Khon Kaen before and after national hepatitis B vaccine program. Asian Pac J Cancer Prev 9 (2008), 507–509.
29. 29 Kew, MC, Hepatocellular carcinoma in developing countries: prevention, diagnosis, and treatment. World J Hepatol 4 (2012), 99–104.